Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 1, 2012, Pages 84-93

  Papamichalis, Panagiotis ^a   Alexiou, Alexis ^a   Boulbou, Maria ^a   Dalekos, George N ^a   Rigopoulou, Eirini I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MELPHALAN; MEPREDNISONE; PREDNISONE; RITUXIMAB; TENOFOVIR; VINBLASTINE; VINCRISTINE;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; MALE; NONHODGKIN LYMPHOMA; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSION; MALE; NUCLEOTIDES; PRODRUGS; RISK; SECONDARY PREVENTION; TIME FACTORS; VIRUS ACTIVATION;

EID: 84856721255     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.07.018     Document Type: Article

References (60)

1. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009, 29(Suppl. 1):1-8.
2. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009, 113:3147-3153.
3. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
4. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
5. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., Demirer T., Dini G., Einsele H., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006, 37:439-449.
6. Stefos A., Gatselis N., Zachou K., Rigopoulou E., Hadjichristodoulou C., Dalekos G.N. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur J Intern Med 2009, 20:35-43.
7. Raptopoulou M., Papatheodoridis G., Antoniou A., Ketikoglou J., Tzourmakliotis D., Vasiliadis T., et al. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. J Viral Hepat 2009, 16:195-202.
8. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
9. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
10. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
11. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
12. Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344:68-69.
13. Westhoff T.H., Jochimsen F., Schmittel A., Stoffler-Meilicke M., Schafer J.H., Zidek W., et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003, 102:1930.
14. Tsutsumi Y., Tanaka J., Kawamura T., Miura T., Kanamori H., Obara S., et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004, 83:58-60.
15. Sarrecchia C., Cappelli A., Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005, 11:189-191.
16. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005, 46:1085-1089.
17. Sera T., Hiasa Y., Michitaka K., Konishi I., Matsuura K., Tokumoto Y., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006, 45:721-724.
18. Garcia-Rodriguez M.J., Canales M.A., Hernandez-Maraver D., Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. Am J Hematol 2008, 83:673-675.
19. Hanbali A., Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009, 84:195.
20. Borentain P., Colson P., Coso D., Bories E., Charbonnier A., Stoppa A.M., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010, 17:807-815.
21. Lee I.C., Huang Y.H., Chu C.J., Lee P.C., Lin H.C., Lee S.D. Hepatitis B virus reactivation after 23months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010, 73:156-160.
22. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
23. Watanabe M., Shibuya A., Tsunoda Y., Danbara M., Ishii R., Ohsaka M., et al. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int 2011, 31:340-347.
24. Aubourg A., d'Alteroche L., Senecal D., Gaudy C., Bacq Y. Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation. Gastroenterol Clin Biol 2007, 31:97-99.
25. Webster A., Brenner M.K., Prentice H.G., Griffiths P.D. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989, 4:207-208.
26. Senecal D., Pichon E., Dubois F., Delain M., Linassier C., Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 1999, 24:1243-1244.
27. Dreger P., Rautenberg P., Kneba M., Schmitz N. Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC. Bone Marrow Transplant 2000, 26:114-116.
28. Endo T., Sawada K., Fujimoto K., Yamamoto S., Takashima H., Haseyama Y., et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki 2000, 41:322-328.
29. Goyama S., Kanda Y., Nannya Y., Kawazu M., Takeshita M., Niino M., et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002, 43:2159-2163.
30. Uhm J.E., Kim K., Lim T.K., Park B.B., Park S., Hong Y.S., et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:463-468.
31. Palmore T.N., Shah N.L., Loomba R., Borg B.B., Lopatin U., Feld J.J., et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009, 7:1130-1137.
32. Koff R.S., Slavin M.M., Connelly J.D., Rosen D.R. Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. Gastroenterology 1977, 72:297-300.
33. Chisari F.V. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997, 99:1472-1477.
34. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1139-1449.
35. Wursthorn K., Wedemeyer H., Manns M.P. Managing HBV in patients with impaired immunity. Gut 2010, 59:1430-1445.
36. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104-1108.
37. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
38. Georgiadou S.P., Zachou K., Liaskos C., Gabeta S., Rigopoulou E.I., Dalekos G.N. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009, 29:434-442.
39. Georgiadou S.P., Zachou K., Rigopoulou E., Liaskos C., Mina P., Gerovasilis F., et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004, 11:358-365.
40. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49(Suppl. 5):S156-S165.
41. Aksoy S., Harputluoglu H., Kilickap S., Dede D.S., Dizdar O., Altundag K., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
42. Milich D.R., Chen M., Schödel F., Peterson D.L., Jones J.E., Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997, 94:14648-14653.
43. Lazdina U., Alheim M., Nyström J., Hultgren C., Borisova G., Sominskaya I., et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003, 84:139-146. [PMID: 12533710].
44. Evens A.M., Jovanovic B.D., Su Y.C., Raisch D.W., Ganger D., Belknap S.M., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011, 22:1170-1180.
45. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
46. Viganò M., Vener C., Lampertico P., Annaloro C., Pichoud C., Zoulim F., et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011, 46:125-131.
47. Chen P.M., Fan S., Liu C.J., Hsieh R.K., Liu J.H., Chuang M.W., et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990, 49:708-713.
48. Seth P., Alrajhi A.A., Kagevi I., Chaudhary M.A., Colcol E., Sahovic E., et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002, 30:189-194.
49. Knöll A., Pietrzyk M., Loss M., Goetz W.A., Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005, 79:1631-1633.
50. Abdelmalek M.F., Pasha T.M., Zein N.N., Persing D.H., Wiesner R.H., Douglas D.D. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003, 9:1253-1257.
51. Ferraro D., Pizzillo P., Di Marco V., Vultaggio A., Iannitto E., Venezia G., et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. Liver Int 2009, 29:1171-1177.
52. Chesnut R.W., Grey H.M. Antigen presentation by B cells and its significance in T-B interactions. Adv Immunol 1986, 39:51-94.
53. Lau G.K., Suri D., Liang R., Rigopoulou E.I., Thomas M.G., Mullerova I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002, 122:614-624.
54. Onozawa M., Hashino S., Izumiyama K., Kahata K., Chuma M., Mori A., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79:616-619.
55. Ceneli O., Ozkurt Z.N., Acar K., Rota S., Aki S.Z., Yeĝin Z.A., et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010, 16:1765-1771.
56. Knöll A., Boehm S., Hahn J., Holler E., Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007, 14:478-483.
57. Onozawa M., Hashino S., Darmanin S., Okada K., Morita R., Takahata M., et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008, 14:1226-1230.
58. Saadoun D., Landau D.A., Calabrese L.H., Cacoub P.P. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007, 46:1234-1242.
59. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27:1670-1677.
60. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 45:S174-S184.